SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing innovative therapies for a wide range of cancer indications. Their primary focus is on the development of novel therapeutics that target the Wilms tumor 1 (WT1) protein, which is overexpressed in numerous cancer types. Their lead product candidate, galinpepimut-S (GPS), is a WT1-targeting cancer immunotherapeutic that has shown promise in clinical trials for treating acute myeloid leukemia (AML), malignant pleural mesothelioma (MPM), and multiple myeloma (MM).

SELLAS is also developing SLS009, a small molecule, highly selective CDK9 inhibitor, licensed from GenFleet Therapeutics (Shanghai), Inc. SLS009 has the potential to be a first-in-class differentiated CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. The company is conducting Phase 1 clinical trials for SLS009 in China and the United States in patients with relapsed/refractory AML, chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and lymphoma.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing novel therapies for a broad range of cancer indications. Their mission is to provide innovative and effective treatments that address the unmet medical needs of cancer patients, ultimately improving their quality of life and survival outcomes. They focus on developing two primary product candidates: galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic, and SLS009, a highly selective small molecule CDK9 inhibitor. SELLAS is committed to bringing these therapies to patients as quickly as possible through a combination of clinical trials, partnerships, and a focus on scientific advancements.

SELLAS Life Sciences fosters a collaborative and results-driven culture, prioritizing innovation and a commitment to developing novel therapies for cancer patients. The company values dedication, teamwork, and a shared passion for making a difference in the lives of those battling cancer. This translates into a dynamic and supportive work environment where employees are encouraged to contribute their expertise and drive towards achieving SELLAS' mission.

SELLAS Life Sciences Group, Inc. does not explicitly state their approach to diversity, equity, and inclusion on their website. However, their company website does feature a Board of Directors diversity matrix that breaks down board members by gender and race.